An overview of the progress in the treatment of multiple myeloma

Robert A. Kyle, S. Vincent Rajkumar

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Effective therapy for multiple myeloma has existed for a little more than the last half century. The introduction of melphalan 55 years ago was followed by a stagnant period of four decades in which many combinations of alkylating agents and chemotherapeutic drugs were developed without a significant increase in overall survival. The first novel agent, thalidomide, was introduced 15 years ago when it was used as an anti-angiogenesis agent. This was followed by a proteasome inhibitor, bortezomib. Then lenalidomide, a second-generation analog of thalidomide was introduced. More recently carfilzomib, a proteasome inhibitor, and pomalidomide, a third-generation derivative of thalidomide have entered the marketplace. Many new agents are in development and potentially available for future therapy.

Original languageEnglish (US)
Pages (from-to)5-7
Number of pages3
JournalExpert Review of Hematology
Issue number1
StatePublished - Feb 2014


  • historical features
  • melphalan
  • multiple myeloma
  • novel agents
  • stem cell transplantation

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'An overview of the progress in the treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this